In P-388 bearing BDF 1 mice stem cell mobilisation was tested on the survival of lethally irradiated isologous recipients. Contamination of the graft with lymphoma cells was evaluated by the number of clonogenic lymphoma cells (CFU-L) and the ability of the graft to induce lymphoma in non-irradiated recipients. A mobilisation protocol (200 mg/kg cyclophosphamide (CY) i.p. or 200 mg/kg CY followed by 125 g/kg G-CSF administered every 12 h for 3 consecutive days, starting 14 days after lymphoma initiation) that resulted in a substantial stem cell mobilisation in normal mice, mobilised too few CFU-L to induce lymphoma in the recipients: 50 l of blood obtained after mobilisation protected lethally irradiated mice but did not induce lymphoma in normal recipients. A minimum graft of bone marrow (2 × 10 5 cells, with 5580 CFU-L) from untreated P-388 bearing donors killed irradiated recipients presumably by lymphoma and not bone marrow failure. The mobilisation protocol reduced CFU-L so much that no lymphoma-associated death occurred even after the transplantation of 10 × 10 5 bone marrow cells. These data suggest that, although the PBSC mobilisation protocol may also mobilise some clonogenic lymphoma cells, with the minimum graft size no lymphoma transfer can be observed.
The use of peripheral blood stem cells (PBSC) for autologous transplantation has increased in recent years. In Europe 90% of the autologous transplantations reported in 1996 were PBSC derived. 1 The advantages of PBSC are well known, but it is not known whether or not PBSCs have an unlimited self-renewal capacity.
Animal experiments have suggested that the quality of stem cells obtained from normal blood is poor, ie the ratio of stem cells with low self-renewal capacity is much higher in the blood than in the bone marrow. 2 Stem cells mobilised into the circulation by various agents or by G-CSF seem to have a better self-renewal capacity [3] [4] [5] approaching that of the bone marrow.
Contamination of PBSC with tumour cells in patients with solid tumours has already been proved. 6 The patho- logical significance of re-infusion of tumour, lymphoma or leukaemia cells is rather obscure. 7 According to Gale 8 at least some relapses of autotransplanted ALL patients derive from leukaemia cells re-infused with the graft.
One has to be aware that neither detectable leukaemia cells nor clonogenic leukaemia cells represent true leukaemia stem cells. To assay leukaemia stem cells one of the best approaches would be a suitable animal model where the incidence of leukaemia development can be assayed directly in the recipients of mobilised stem cells.
In the present paper such an experimental model for possible contamination of mobilised PBSC in a murine lymphoma is offered. For stem cell mobilisation a protocol widely used in clinical practice (cyclophosphamide followed by G-CSF) was applied.
Materials and methods

Experimental animals and lymphoma induction
Twelve-to 14-week-old BDF 1 female mice were used. P-388 cells were maintained in suspension cultures by serial passage every 3rd day, with occasional intervals of storage in liquid nitrogen. In standard experiments 1 × 10 5 cells were injected i.p. This cell dose induced 100% mortality with a median survival time of 20 days.
Spleen colony-forming cell (CFU-S) assay and stem cell transplantation
Recipients were irradiated with 9 Gy from a 60 Co ␥ source and injected with cells from isologous donors. Spleen colonies were counted on day 9. In transplantation experiments the minimum graft size (assayed in pilot experiments: 2 × 10 5 bone marrow cells or 50 or 100 l blood after stem cell mobilisation) was injected, and survival was followed for 60 days.
Assay of granulocyte-macrophage colony-forming cells (CFU-GM) and lymphoma colony-forming cells (CFU-L)
Standard agar colony assays were used. For CFU-GM 10% WEHI 3-B cell conditioned medium was used as the CSF source. CFU-L were assayed without added CSF. Colonies (ie aggregates of more than 50 cells) were counted on day 7.
Mobilisation of stem cells and progenitor cells
Fourteen days after inoculation of P-388 cells 200 mg/kg cyclophosphamide (CY, Cytoxan; Bristol-Myers Squibb, Baar, Switzerland) was injected i.p. 6 days before exsanguination of the animals. G-CSF (recombinant human G-CSF, Neupogen; F Hoffman-La Roche, Basel, Switzerland) was injected s.c. in a daily dose of 250 g, divided into two equal doses on days 3, 4, 5 and 6 after CY administration. Mice were exsanguinated from the axillary vessels 3 h after the last injection and the number of circulating CFU-S, CFU-GM, CFU-L was assayed.
Assay of lymphoma inducing cells
Fifty or 100 l blood or 2 × 10 5 bone marrow cells were injected into non-irradiated isologous recipients i.p. and survival was followed for 90 days.
Results
First, the number of mobilizable stem and progenitor cells (CFU-S and CFU-GM) were studied in normal BDF 1 mice. Six days after the injection of 200 mg/kg CY more than 1000 CFU-S and CFU-GM per ml blood could be detected. Transplantation of 50 l blood (= 54.5 Ϯ 12.5 CFU-S), corresponding to the minimum graft size assayed in pilot experiments, resulted in 70% survival of lethally irradiated recipients. If G-CSF was administered twice daily for 3 consecutive days following CY injection, an even more pronounced mobilisation of CFU-S and CFU-GM was observed and nearly 100% survival could be obtained by injecting 50 l blood (= 75.4 Ϯ 34.5 CFU-S) (Table 1a) The same mobilisation protocol resulted in a substantial clonogenic cell mobilisation in P-388 lymphoma bearing BDF 1 mice. By transplantation of 50-100 l blood (150-675 CFU-GM) 70-80% of lethally irradiated recipients survived. If, however, blood cells from P-388 lymphoma bearing untreated mice were transplanted, none of the lethally irradiated recipients survived, possibly due to the large number of contaminating leukaemogenic cells (Table 1b) .
Next, the contamination of the 50-100 l blood with lymphoma inducing cells was studied. Following the above mentioned mobilisation protocol 50-100 l blood contained only a few CFU-L and no lymphoma was observed in the recipient mice. Fifty l blood from untreated lymphoma bearing mice, however, contained more than 7000 CFU-L, inducing 100% lymphoma mortality of the recipients with a median survival time of 17 days (Table 1c.) To obtain data on the relationship between the number of transplanted CFU-GM, contaminating lymphoma cells and survival rate of lethally irradiated recipients, mice were injected with increasing numbers of bone marrow cells from P-388 bearing donors. With 2 × 10 5 bone marrow cells from untreated P-388 bearing donors 5580 CFU-L were injected and no survival was observed. From CY treated mice with 2 × 10 5 bone marrow cells less than three clonogenic lymphoma cells were injected and nine of 10 recipients survived. Even with 1 × 10 6 bone marrow cells only 28 CFU-L were injected and the survival rate was 7/10 (Table 2a) .
From bone marrow of lymphoma bearing mice even a low cell dose (0.5 × 10 5 ) induced 100% mortality of normal mice with a median survival rate of 19.5 days. If mice were treated with CY or a combination of CY and G-CSF as used in the mobilisation protocol, in 10 5 bone marrow cells none or only a few CFU-L could be detected and no lym- a Calculated from number of colonies grown without added conditioned medium. b Bone marrow was collected 6 days after 200 mg/kg CY i.p. c 200 mg/kg CY on day −6, followed by 125 g/kg/12 h Hu-rG-CSF on days −3, −2, −1 and 3 h before obtaining bone marrow cells.
phoma-induced mortality of unirradiated recipient mice occurred when injected with 1-2 × 10 5 bone marrow cells (Table 2b) .
Discussion
Circulating tumour cells have already been detected in the peripheral blood of patients with lymphoma or breast cancer [9] [10] [11] or in children with disseminated neuroblastoma 12 and an increased occurrence of tumour cells upon mobilisation of PBSCs in stage IV breast cancer patients has also been reported. 6 Although only a fraction of circulating tumour cells can be regarded as tumour inducing cells (tumour stem cells), the retrovirally marked neuroblastoma cells could be detected in bone marrow of autotransplanted patients in relapse. 7 Consequently re-infusion of a graft that contains clonogenic tumour cells has to be taken into consideration when indicating autologous transplantation.
A suitable animal model may expand our knowledge on leukaemogenic cell contamination of mobilised PBSC. The Brown Norway rat myelocyte leukaemia model 13,14 offered a mathematical perspective on the role of contaminating leukaemia cells in the graft in relation to leukaemia relapse. The present data suggested that in P-388 lymphoma bearing mice CY and CY + G-CSF mobilisation (a PBSC mobilisation protocol widely used in clinical practice) mobilised enough stem cells (150-675 CFU-S in 50-100 l blood) to protect lethally irradiated recipients. Although this mobilisation protocol may also mobilise lymphoma stem cells, blood volume regarded as the minimum graft size contained too few leukaemogenic cells (130 CFU-L injected into lethally irradiated recipients and 88 injected into normal mice) to induce lymphoma. Although clonogenic lymphoma cells (CFU-L) are presumably not identical to lymphoma stem cells, some parallelism between CFU-L and lymphoma stem cells may be presumed. Consequently, the number of CFU-L may give some information about the lymphoma stem cell contamination of the graft. In CY-treated mice (200 mg/kg, close to the LD 10 value of CY) 15 with 1 × 10 6 bone marrow cells only 28 CFU-L were injected and no lymphoma was observed in the recipients. Following mobilisation, 100 l blood contained only 88 CFU-L and seven of eight injected normal mice survived. Supralethally irradiated mice received 130 CFU-L with the injected blood volume, time of death suggested that the 30% mortality rate was probably due to bone marrow failure rather than to lymphoma-associated death. This fits well into the ED 50 theory by Schultz et al 14 in that (1) the quantity of inoculated cells can be regarded as a number of ED 50 units and (2) the chance of leukaemia development from the graft increases with increasing cell dose or decreasing ED 50 value. Although we did not determine the ED 50 value for cells derived from CY-treated mice in the present experiments, the second possibility seemed likely. Thus, by reducing the lymphoma cell burden, the injected PBSC did not induce lymphoma.
The fact that G-CSF mobilises PBSC with high selfrenewal potential in the murine setting and can maintain lifelong polyclonal haemopoiesis in recipients, 16 underlines the importance of multifaceted proof of lack of lymphoma inducing cells transplanted with the graft. In our laboratory further studies are in progress to prove that data obtained on the murine P-388 lymphoma are valid for other murine leukaemias.
